Latest Schedule 13G passive stakes

ADAR1 Capital Management and Daniel Schneeberger have updated their beneficial ownership filing for Spruce Biosciences, Inc., reporting a 2.5% stake as of June 30, 2026.

Several Venrock-affiliated entities have collectively reported beneficial ownership of 9.9% of VOR Biopharma's common stock as of June 30, 2026, due to a beneficial ownership blocker.

Split Rock Partners and associated entities have filed a Schedule 13G, reporting beneficial ownership of 2,937,570 shares of EBR Systems, Inc. common stock, representing 3.9% of the outstanding shares.

Venrock Healthcare Capital Partners III, L.P. and affiliated entities report a beneficial ownership of 4.7% of Tenax Therapeutics, Inc. common stock, primarily through warrants.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, have jointly filed an amendment to Schedule 13G, reporting a combined beneficial ownership of 98,101,407 shares of LifeStance Health Group, Inc. common stock, representing 25.7% of the outstanding shares.

Fourthstone LLC and associated entities have filed an amendment to their Schedule 13G, reporting changes in beneficial ownership of Parke Bankcorp, Inc. common stock.

Several Venrock-affiliated entities and individuals have reported a combined beneficial ownership of 7.4% in Oruka Therapeutics, Inc. common stock as of June 30, 2026.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filings for MainStreet Bancshares, Inc., reporting a combined holding of 0.67% of the company's common stock as of June 30, 2026.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filings for Investar Holding Corp, reporting a combined 2.34% stake.

Samsara BioCapital entities and Srinivas Akkaraju have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Eloxx Pharmaceuticals' common stock.

Fourthstone LLC and affiliated entities have updated their beneficial ownership filing for Hanover Bancorp, Inc., reporting a combined 2.02% stake.

Several Fourthstone-affiliated entities have filed a Schedule 13G, reporting 0.00% beneficial ownership of First National Corporation's common stock.

Caligan Partners LP and David Johnson have reported beneficial ownership of 7,967,207 shares, representing 8.8% of SAB Biotherapeutics, Inc. common stock.

KalVista Pharmaceuticals, Inc. has filed an amendment to its Schedule 13G, reporting on beneficial ownership as of June 30, 2026.

Fourthstone LLC and affiliated entities report a passive ownership stake in FVCBankcorp, Inc. as of June 30, 2026.

Investment firm Two Seas Capital LP, along with its GP and chief investment officer Sina Toussi, has reported beneficial ownership of 7.5% of Calumet, Inc.'s common stock as of June 30, 2026.

CH4 Natural Solutions Acquisition Sponsor LLC and related entities report beneficial ownership of 7,333,334 Class B ordinary shares, convertible to Class A, representing 24.8% of the outstanding shares as of August 14, 2026.

Helen of Troy Limited has filed an amendment to its Schedule 13G, detailing changes in beneficial ownership of its common stock.

A group of investment entities, including Venrock Healthcare Capital Partners, has reported a combined beneficial ownership of 8.3% in Jade Biosciences, Inc. as of June 30, 2026.

Multiple Fourthstone-affiliated investment entities and L. Phillip Stone IV have collectively reported beneficial ownership of approximately 7.01% of First Northern Community Bancorp's common stock.

Two Seas Capital LP, along with its general partner and chief investment officer, has reported beneficial ownership of 2,488,535 shares, representing 6.3% of Quantum Corporation's common stock as of June 30, 2026.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, has reported a joint beneficial ownership of 2,975,566 shares, representing 7.8% of Ceribell, Inc.'s common stock.

Multiple Venrock-affiliated entities have reported a complete divestment of their holdings in enGene Holdings Inc. as of June 30, 2026.

Several Fourthstone-affiliated investment entities have collectively reported beneficial ownership of 8.97% of F&M Bank Corp's common stock as of June 30, 2026.

A Schedule 13G filing reveals updated beneficial ownership information for Carter's, Inc. by RWWM, Inc. and associated individuals.

Several Venrock-affiliated entities and individuals have disclosed a combined beneficial ownership of 4.2% of Artiva Biotherapeutics, Inc.'s common stock as of June 30, 2026.

Investment firm Two Seas Capital LP, along with its GP and CIO Sina Toussi, has disclosed beneficial ownership of 3,092,234 shares, representing 9.1% of Nektar Therapeutics' common stock as of June 30, 2026.

Whitefort Capital Management, LP, along with its Co-Managing Partners David Salanic and Joseph Kaplan, now beneficially own 7.1% of OmniAb, Inc. common stock.

Multiple entities associated with Venrock Healthcare Capital Partners have updated their beneficial ownership of Adlai Nortye Ltd. Class A Ordinary Shares.

Investment adviser Fourthstone LLC and affiliated entities have reported beneficial ownership of 329,498 shares, representing 9.14% of Foresight Financial Group Inc.'s common stock.